Genetic testing may soon become a determining factor in treatment for peritoneal mesothelioma. The recent findings of a retrospective study found a major drop in overall survival and progression-free survival among patients with alterations in the CDKN2A and NF2 genes. The prognostic significance of the two genetic clues could change the way doctors determine a patient's eligibility for major aggressive surgery. Modern Pathology published the study last month. Officials at the University of Pittsburgh Medical Center (UPMC) and Emory University School of Medicine in Atlanta supplied the research. The study involved 86 patients who were previously treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemoperfusion (HIPEC). "The status of these genes has significan...
from MedWorm: Mesothelioma http://www.medworm.com/index.php?rid=146797248&cid=c_409_55_f&fid=36962&url=http%3A%2F%2Fwww.asbestos.com%2Fnews%2F2015%2F11%2F02%2Fgenetic-testing-peritoneal-mesothelioma%2F
Enregistrer un commentaire